These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

213 related items for PubMed ID: 15269082

  • 1. Coronary risk factors in Kawasaki disease treated with additional gammaglobulin.
    Miura M, Ohki H, Tsuchihashi T, Yamagishi H, Katada Y, Yamada K, Yamashita Y, Sugaya A, Komiyama O, Shiro H.
    Arch Dis Child; 2004 Aug; 89(8):776-80. PubMed ID: 15269082
    [Abstract] [Full Text] [Related]

  • 2. Pentoxifylline and intravenous gamma globulin combination therapy for acute Kawasaki disease.
    Furukawa S, Matsubara T, Umezawa Y, Motohashi T, Ino T, Yabuta K.
    Eur J Pediatr; 1994 Sep; 153(9):663-7. PubMed ID: 7957426
    [Abstract] [Full Text] [Related]

  • 3. Predictors of coronary artery lesions after intravenous gamma-globulin treatment in Kawasaki disease.
    Mori M, Imagawa T, Yasui K, Kanaya A, Yokota S.
    J Pediatr; 2000 Aug; 137(2):177-80. PubMed ID: 10931408
    [Abstract] [Full Text] [Related]

  • 4. Reevaluation of the efficacy of intravenous gammaglobulin in the prevention and treatment of coronary artery lesion in Kawasaki disease.
    Qin L, Saumu MT, Wang H, Shi H, Hu X, Cheng P.
    J Huazhong Univ Sci Technolog Med Sci; 2005 Aug; 25(3):348-50, 370. PubMed ID: 16201293
    [Abstract] [Full Text] [Related]

  • 5. Comparison of Risk of Recrudescent Fever in Children With Kawasaki Disease Treated With Intravenous Immunoglobulin and Low-Dose vs High-Dose Aspirin.
    Platt B, Belarski E, Manaloor J, Ofner S, Carroll AE, John CC, Wood JB.
    JAMA Netw Open; 2020 Jan 03; 3(1):e1918565. PubMed ID: 31899532
    [Abstract] [Full Text] [Related]

  • 6. Intravenous gamma-globulin for Kawasaki disease.
    Furusho K, Kamiya T, Nakano H, Kiyosawa N, Shinomiya K, Hayashidera T, Tamura T, Hirose O, Manabe Y, Yokoyama T.
    Acta Paediatr Jpn; 1991 Dec 03; 33(6):799-804. PubMed ID: 1801560
    [Abstract] [Full Text] [Related]

  • 7. Predictive risk factors for coronary artery abnormalities in Kawasaki disease.
    Kim T, Choi W, Woo CW, Choi B, Lee J, Lee K, Son C, Lee J.
    Eur J Pediatr; 2007 May 03; 166(5):421-5. PubMed ID: 17033807
    [Abstract] [Full Text] [Related]

  • 8. Ulinastatin, a urinary trypsin inhibitor, for the initial treatment of patients with Kawasaki disease: a retrospective study.
    Kanai T, Ishiwata T, Kobayashi T, Sato H, Takizawa M, Kawamura Y, Tsujimoto H, Nakatani K, Ishibashi N, Nishiyama M, Hatai Y, Asano Y, Kobayashi T, Takeshita S, Nonoyama S.
    Circulation; 2011 Dec 20; 124(25):2822-8. PubMed ID: 22104548
    [Abstract] [Full Text] [Related]

  • 9. Prognostic impact of vascular leakage in acute Kawasaki disease.
    Terai M, Honda T, Yasukawa K, Higashi K, Hamada H, Kohno Y.
    Circulation; 2003 Jul 22; 108(3):325-30. PubMed ID: 12835221
    [Abstract] [Full Text] [Related]

  • 10. High-dose intravenous gammaglobulin for Kawasaki disease.
    Furusho K, Kamiya T, Nakano H, Kiyosawa N, Shinomiya K, Hayashidera T, Tamura T, Hirose O, Manabe Y, Yokoyama T.
    Lancet; 1984 Nov 10; 2(8411):1055-8. PubMed ID: 6209513
    [Abstract] [Full Text] [Related]

  • 11. [Risk factors for coronary artery lesions in children with Kawasaki disease].
    Li Y, Wang XM, Liu YL, Shi K, Yang YF, Guo YH.
    Zhongguo Dang Dai Er Ke Za Zhi; 2012 Dec 10; 14(12):938-41. PubMed ID: 23234782
    [Abstract] [Full Text] [Related]

  • 12. Risk factors associated with the need for additional intravenous gamma-globulin therapy for Kawasaki disease.
    Muta H, Ishii M, Furui J, Nakamura Y, Matsuishi T.
    Acta Paediatr; 2006 Feb 10; 95(2):189-93. PubMed ID: 16449025
    [Abstract] [Full Text] [Related]

  • 13. Risk factors for coronary artery lesions in children with Kawasaki disease.
    Duan J, Jiang H, Lu M.
    Arch Argent Pediatr; 2020 Oct 10; 118(5):327-331. PubMed ID: 32924395
    [Abstract] [Full Text] [Related]

  • 14. A Multicenter Study of Intravenous Immunoglobulin Non-response in Kawasaki Disease.
    Wei M, Huang M, Chen S, Huang G, Huang M, Qiu D, Guo Z, Jiang J, Zhou X, Yu Q, Guo Y, Fu L, Gao W, Li F.
    Pediatr Cardiol; 2015 Aug 10; 36(6):1166-72. PubMed ID: 25812827
    [Abstract] [Full Text] [Related]

  • 15. Early intravenous gamma-globulin treatment for Kawasaki disease: the nationwide surveys in Japan.
    Muta H, Ishii M, Egami K, Furui J, Sugahara Y, Akagi T, Nakamura Y, Yanagawa H, Matsuishi T.
    J Pediatr; 2004 Apr 10; 144(4):496-9. PubMed ID: 15069399
    [Abstract] [Full Text] [Related]

  • 16. [Therapeutic effectiveness of intravenous immunoglobulin at 1 g/kg and 2 g/kg on Kawasaki disease: a comparative and follow-up study].
    Qin LJ, Wang HW, Hu XF, Liu QJ, Shi H, Wei YX, Chen QJ, Cheng PX.
    Zhonghua Er Ke Za Zhi; 2006 Dec 10; 44(12):891-5. PubMed ID: 17254453
    [Abstract] [Full Text] [Related]

  • 17. Use of intravenous gamma-globulin for Kawasaki disease: effects on cardiac sequelae.
    Yanagawa H, Nakamura Y, Sakata K, Yashiro M.
    Pediatr Cardiol; 1997 Dec 10; 18(1):19-23. PubMed ID: 8960487
    [Abstract] [Full Text] [Related]

  • 18. Efficacy of plasmin-treated intravenous gamma-globulin for therapy of Kawasaki syndrome.
    Hsu CH, Chen MR, Hwang FY, Kao HA, Hung HY, Hsu CH.
    Pediatr Infect Dis J; 1993 Jun 10; 12(6):509-12. PubMed ID: 8345983
    [Abstract] [Full Text] [Related]

  • 19. Elevated D-dimer level is a risk factor for coronary artery lesions accompanying intravenous immunoglobulin-unresponsive Kawasaki disease.
    Masuzawa Y, Mori M, Hara T, Inaba A, Oba MS, Yokota S.
    Ther Apher Dial; 2015 Apr 10; 19(2):171-7. PubMed ID: 25257673
    [Abstract] [Full Text] [Related]

  • 20. Treatment of acute Kawasaki disease: aspirin's role in the febrile stage revisited.
    Hsieh KS, Weng KP, Lin CC, Huang TC, Lee CL, Huang SM.
    Pediatrics; 2004 Dec 10; 114(6):e689-93. PubMed ID: 15545617
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 11.